These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1313173)

  • 1. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
    Qian MX; Swagler AR; Mehta M; Vishwanathan CT; Gallo JM
    Pharm Res; 1992 Feb; 9(2):224-7. PubMed ID: 1313173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of anti-HIV nucleosides in microswine.
    Swagler AR; Qian MX; Gallo JM
    J Pharm Pharmacol; 1991 Dec; 43(12):823-6. PubMed ID: 1687578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic evaluation of drug interactions with anti-HIV drugs, II: Effect of 2',3'-dideoxyinosine (ddI) on zidovudine kinetics in monkeys.
    Gallo JM; Finco TS; Swagler AR; Mehta MU; Viswanathan CT; Qian M
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):277-83. PubMed ID: 1540413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys.
    Qian M; Swagler AR; Fong KL; Crysler CS; Mehta M; Gallo JM
    Drug Metab Dispos; 1992; 20(3):396-401. PubMed ID: 1355714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. VI. Effect of the calcium channel blocker nimodipine on zidovudine kinetics in monkeys.
    Gallo JM; Swagler AR; Mehta M; Qian M
    J Pharmacol Exp Ther; 1993 Jan; 264(1):315-20. PubMed ID: 8423534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys.
    Qian MX; Finco TS; Mehta M; Viswanathan CT; Gallo JM
    J Pharm Sci; 1991 Nov; 80(11):1007-11. PubMed ID: 1815049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice.
    Hostetler KY; Richman DD; Sridhar CN; Felgner PL; Felgner J; Ricci J; Gardner MF; Selleseth DW; Ellis MN
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2792-7. PubMed ID: 7695264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
    Spector SA; Ripley D; Hsia K
    Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC.
    Peghini PA; Zahner R; Kuster H; Schott H; Schwendener RA
    Antivir Chem Chemother; 1998 Mar; 9(2):117-26. PubMed ID: 9875383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine.
    Kong XB; Zhu QY; Vidal PM; Watanabe KA; Polsky B; Armstrong D; Ostrander M; Lang SA; Muchmore E; Chou TC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):808-18. PubMed ID: 1503443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
    Watanabe KA; Harada K; Zeidler J; Matulic-Adamic J; Takahashi K; Ren WY; Cheng LC; Fox JJ; Chou TC; Zhu QY
    J Med Chem; 1990 Aug; 33(8):2145-50. PubMed ID: 1695683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis.
    Singlas E; Pioger JC; Taburet AM; Colin JN; Fillastre JP
    Clin Pharmacol Ther; 1989 Aug; 46(2):190-7. PubMed ID: 2758728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T; Yarchoan R; O'Brien MC; Husson RN; Anderson BD; Kojima E; Shimada T; Broder S; Mitsuya H
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):562-6. PubMed ID: 8380641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex.
    Meng TC; Fischl MA; Richman DD
    Am J Med; 1990 May; 88(5B):27S-30S. PubMed ID: 2159707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.
    Klecker RW; Collins JM; Yarchoan RC; Thomas R; McAtee N; Broder S; Myers CE
    J Clin Pharmacol; 1988 Sep; 28(9):837-42. PubMed ID: 2852679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats.
    Mays DC; Dixon KF; Balboa A; Pawluk LJ; Bauer MR; Nawoot S; Gerber N
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1261-70. PubMed ID: 1762074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-resistance of dideoxycytidine-resistant cell lines to azidothymidine.
    Agarwal RP; Wang W; Yo P; Han T; Fernandez M
    Biochem Pharmacol; 1999 Nov; 58(10):1603-8. PubMed ID: 10535751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study.
    Meng TC; Fischl MA; Boota AM; Spector SA; Bennett D; Bassiakos Y; Lai SH; Wright B; Richman DD
    Ann Intern Med; 1992 Jan; 116(1):13-20. PubMed ID: 1345755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of interaction between zidovudine and 4-methyl-amino-antipyrine, the active metabolite of metamizole, in human liver in vitro.
    Bacracheva N; Kamali F
    Methods Find Exp Clin Pharmacol; 1995 Jun; 17(5):299-301. PubMed ID: 8830197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT.
    Schwendener RA; Peghini PA; Ludwing PS; Schott H
    Nucleosides Nucleotides; 1999; 18(4-5):949-50. PubMed ID: 10432717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.